How should I manage a 40-year-old male with persistent erectile dysfunction, decreased libido, fatigue, myalgias, anhedonia, and carbohydrate cravings 3–4 weeks after stopping finasteride, who is currently taking sertraline, has normal thyroid function, normal prolactin, normal cortisol, normal testosterone, elevated sex hormone‑binding globulin, low dihydrotestosterone, and isolated leukopenia?

Management Recommendation: Address Sertraline as Primary Culprit

The most appropriate next step is to discuss switching from sertraline to a sexually-neutral antidepressant such as bupropion, given that his comprehensive hormonal workup is essentially normal and sertraline remains the most likely ongoing contributor to his persistent sexual dysfunction. 1, 2

Key Clinical Findings

Your patient's laboratory results reveal:

• Normal testosterone axis: Total testosterone 919 ng/dL (excellent), free testosterone 109.4 pg/mL (normal)
• Elevated SHBG: 58 nmol/L (high) - but this is not clinically significant given his robust total and free testosterone levels
• Normal DHT: 56 ng/dL with free DHT 2.36 pg/mL
• Normal thyroid, prolactin, and metabolic parameters
• Isolated mild leukopenia: WBC 2.62 (requires monitoring but unlikely related to sexual symptoms)

Primary Management Strategy

1. Medication Modification (Priority Action)

The evidence strongly supports that SSRIs like sertraline cause sexual dysfunction in up to 25% of patients through direct effects on libido, erectile function, and ejaculation 1. The FDA label for sertraline explicitly warns of sexual dysfunction that can persist after discontinuation 2.

Specific recommendation:

• Discuss transitioning from sertraline to bupropion, which has a sexually-neutral profile 1
• Explain that while post-finasteride syndrome exists 3, 4, 5, his symptoms at 3-4 weeks post-discontinuation are still within the typical resolution timeframe
• Set realistic expectations: Most finasteride-related symptoms resolve within 2-3 months of discontinuation, but sertraline's ongoing presence is likely preventing recovery

2. Address the Post-Finasteride Syndrome Concern

While post-finasteride syndrome (PFS) is documented in FDA labeling 3 and research 4, 5, 6, several factors argue against this being established PFS:

• Timeline: Only 3-4 weeks post-discontinuation (too early to diagnose persistent syndrome)
• Confounding factor: Concurrent sertraline use, which independently causes identical sexual symptoms 1, 2
• Normal hormonal profile: His testosterone, DHT, and other hormones are normal, whereas some PFS cases show hormonal abnormalities

The FDA label notes that sexual dysfunction "continued after discontinuation of treatment" has been reported rarely 3, but distinguishing this from sertraline effects is impossible while he remains on the SSRI.

3. Consider PDE-5 Inhibitor Trial

The American College of Physicians strongly recommends initiating PDE-5 inhibitor therapy for erectile dysfunction 7. This is a Grade A, high-quality evidence recommendation.

Specific approach:

• Offer sildenafil, tadalafil, or vardenafil based on patient preference, cost, and convenience 7
• Explain this can provide symptomatic relief while addressing the underlying medication issue
• No contraindications identified (normal cardiovascular exam, no nitrate use)

4. Address Associated Symptoms

His constellation of fatigue, myalgias, anhedonia, and carbohydrate cravings warrant consideration:

Depression screening: His PHQ-9 score of 0 is reassuring, but these symptoms could represent:

• Subsyndromal depression (sertraline may be inadequately treating his anxiety/mood)
• SSRI-induced apathy syndrome 1
• Post-finasteride neuropsychiatric effects (documented but controversial) 4, 5

Metabolic considerations: His A1C of 5.1% is excellent, ruling out diabetes as a contributor to fatigue or sexual dysfunction 1

5. Monitor the Leukopenia

WBC 2.62 with absolute neutrophil count 1.43 requires:

• Repeat CBC in 2-4 weeks
• Consider infectious disease or hematology referral if persistent or worsening
• Unlikely related to sexual symptoms but needs evaluation

Evidence-Based Timeline and Follow-Up

Immediate (Today's Visit):

• Discuss sertraline as primary ongoing contributor
• Offer antidepressant switch to bupropion (coordinate with prescribing provider if different)
• Prescribe PDE-5 inhibitor for symptomatic relief
• Reassure that 3-4 weeks post-finasteride is too early to diagnose persistent syndrome

4-6 Week Follow-Up:

• Reassess sexual function after sertraline discontinuation/switch
• Repeat CBC for leukopenia monitoring
• Evaluate mood and anxiety symptoms on new regimen

3-Month Follow-Up:

• If symptoms persist despite sertraline cessation, consider true post-finasteride syndrome 4, 5
• At that point, consider specialized evaluation (though no established treatment exists) 8
• The 2009 ACP guidelines note insufficient evidence for hormonal treatment even with documented abnormalities 7, and his hormones are normal

Critical Pitfalls to Avoid

1. Don't attribute everything to post-finasteride syndrome prematurely: The ongoing sertraline use is a more likely and treatable cause 1, 2

2. Don't initiate testosterone therapy: His testosterone levels are excellent (919 ng/dL total, 109.4 pg/mL free). The ACP explicitly recommends against testosterone in men without true hypogonadism 9, and the elevated SHBG is not clinically significant given his robust free testosterone 10

3. Don't dismiss the patient's concerns: Post-finasteride syndrome is real and documented 3, 4, 5, but proper diagnosis requires excluding other causes first

4. Don't delay antidepressant modification: Continuing sertraline while waiting to see if finasteride effects resolve will prevent accurate assessment 1

The evidence strongly supports that psychotropic drugs, particularly SSRIs, affect libido and erectile function through direct mechanisms or by altering prolactin/testosterone 1. Your patient's normal hormonal profile makes medication effects the most likely reversible cause.